The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment. Lilly's share price has surged, with investors betting that an approval will make it a blockbuster drug. Final guidance from NICE is scheduled to be published on Oct. 11 after which the drug will be made available in the UK's National Health Service (NHS) within 90 days.

Related Keywords

United Kingdom , Bengaluru , Karnataka , India , Britain , Maggie Fick , Novo Nordisk Ozempic , Eli Lilly , Edwina Gibbs , Nilutpal Timsina , Ros Russell , Lavanya Ahire , National Institute For Health , Reuters , United Kingdom National Health Service , National Institute , Care Excellence , National Health Service , Novo Nordisk , Diabetes United Kingdom , Type 2 Diabetes , National Institute For Health And Care Excellence , Blockbuster Drug , Drug Class , Diabetes ,